-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Xiansheng Pharmaceutical (02096.HK) announced that on December 7, 2025, Enzeshu® (injectable suvicitamab) has been officially included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2025)” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, and will take effect from January 1, 2026. In addition, Endo® (recombinant human vascular endothelial inhibin injection) has successfully completed the renewal of the National Medical Insurance Drug List (NRDL).

Zhitongcaijing·12/07/2025 23:17:05
Listen to the news
According to Zhitong Finance App, Xiansheng Pharmaceutical (02096.HK) announced that on December 7, 2025, Enzeshu® (injectable suvicitamab) has been officially included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2025)” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, and will take effect from January 1, 2026. In addition, Endo® (recombinant human vascular endothelial inhibin injection) has successfully completed the renewal of the National Medical Insurance Drug List (NRDL).